Salivary Microbiome Predicts Immune-Checkpoint Inhibitor Success in Lung Cancer

Salivary Microbiome Linked to Immune-Checkpoint Inhibitor Effectiveness in Advanced Lung Cancer Researchers have identified a potential connection between the salivary microbiome and the effectiveness of immune-checkpoint inhibitors (ICIs) in treating advanced non-small cell lung cancer (NSCLC). The study, conducted by a team including Cavaliere, Fogolari, and Iuliani, suggests that specific microbial signatures in saliva may serve as indicators of how well patients respond to ICIs, a type of immunotherapy used to combat certain cancers. The findings focus on the presence of Actinomyces bacteria within the salivary microbiome. Researchers observed that patients with higher levels of this microbial signature demonstrated improved responses to ICIs. This discovery could provide new insights into personalized treatment strategies for NSCLC by using saliva samples to predict therapy outcomes. The study highlights the potential role of the microbiome in influencing cancer treatment efficacy and opens avenues for further investigation into its clinical applications. Newsflash | Powered by GeneOnline AI Source: GO-AI-ne1 For any suggestion and feedback, please contact us. Date: January 18, 2026